ROCKVILLE, Md. & EDMONTON, Alberta, April 30, 2024--The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
ROCKVILLE, Md. & EDMONTON, Alberta, April 16, 2024--UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
ROCKVILLE, Md. & EDMONTON, Alberta, April 15, 2024--Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024